Gout-Related Medication Use After Initiating Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Gout and Type 2 Diabetes: Population-Based Target Trial Emulation Studies.
Saved in:
| Title: | Gout-Related Medication Use After Initiating Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Gout and Type 2 Diabetes: Population-Based Target Trial Emulation Studies. |
|---|---|
| Authors: | McCormick N; Rheumatology and Allergy Clinical Epidemiology Research Center, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA.; The Mongan Institute, Department of Medicine, Massachusetts General Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Arthritis Research Canada, Vancouver, British Columbia, Canada., Burrack N; Clinical Research Center, Soroka University Medical Center, Beer-Sheva, Israel., Yokose C; Rheumatology and Allergy Clinical Epidemiology Research Center, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA.; The Mongan Institute, Department of Medicine, Massachusetts General Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Lu N; Arthritis Research Canada, Vancouver, British Columbia, Canada., Wexler DJ; Department of Medicine, Harvard Medical School, Boston, MA.; Diabetes Center, Massachusetts General Hospital, Boston, MA., Rai SK; Rheumatology and Allergy Clinical Epidemiology Research Center, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA.; The Mongan Institute, Department of Medicine, Massachusetts General Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Challener GJ; Rheumatology and Allergy Clinical Epidemiology Research Center, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA.; The Mongan Institute, Department of Medicine, Massachusetts General Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Aviña-Zubieta JA; Arthritis Research Canada, Vancouver, British Columbia, Canada.; Division of Rheumatology, Department of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada., McCoy RG; Division of Endocrinology, Diabetes, and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD.; University of Maryland Institute for Health Computing, North Bethesda, MD., Abuhasira R; Clinical Research Center, Soroka University Medical Center, Beer-Sheva, Israel., Choi HK; Rheumatology and Allergy Clinical Epidemiology Research Center, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA.; The Mongan Institute, Department of Medicine, Massachusetts General Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Arthritis Research Canada, Vancouver, British Columbia, Canada. |
| Source: | Diabetes care [Diabetes Care] 2026 Mar 01; Vol. 49 (3), pp. 460-470. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Diabetes Association Country of Publication: United States NLM ID: 7805975 Publication Model: Print Cited Medium: Internet ISSN: 1935-5548 (Electronic) Linking ISSN: 01495992 NLM ISO Abbreviation: Diabetes Care Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
